Company intelligence / Profile preview

PriGen

Ownership: Private
Development stage: Other

Overview

PriGen is an Italian R&D-focused biotech/pharma company specializing in the development of antibodies, diagnostic reagents, pharmaceutical formulations, and medical devices. It has established collaborations with major academic institutions and pharmaceutical companies. The company offers contract research services as well as proprietary products—especially topical skin care formulations—and has developed innovative platforms for human recombinant antibody production and site-specific PEGylation to enhance therapeutic properties of biologics. No clinical trial results are publicly available.

Therapeutic areas: Infectious DiseasesOncology
Modalities: Monoclonal antibodyPolyclonal antibodyRecombinant proteinProtein-polymer conjugate (e.g., PEGylated proteins)
Industry: Biotech

Partnerships

Collaborations with Italian National Research Council (CNR), Universities of Milan/Naples/Cagliarileading pharmaceutical companies

Beyond the preview

Go deeper on PriGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PriGen.

Explore the full profile